ACTIVATING THE PATIENT'S IMMUNE SYSTEM TO FIGHT CANCER

2Q 2021

18 August 2021



IMPORTANT NOTICE AND DISCLAIMER

This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the financial condition of Targovax. Such forward-looking statements reflect the current views of Targovax and are based on the information currently available to the company. Targovax cannot give any assurance as to the correctness of such statements.

There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following commercialization of the company's products, and liability in connection therewith; risks relating to the company's freedom to operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the company's ability to adequately protect its intellectual property and knowhow; risks relating to obtaining regulatory approval and other regulatory risks relating to the development and future commercialization of the company's ability to successfully commercialize and gain market achieve commercial success; risks relating to the future development of the pricing environment and/or regulations for pharmaceutical products; risks relating to the company's ability to secure additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks relating to the company's ability to retain key personnel; and risks relating to the impact of competition.




Introduction and highlights

- 2. Melanoma
- 3. Finance
- 4. Summary



TARGOVAX AT A GLANCE



ONCOS-102: Novel immune activator with clinical efficacy in several solid tumors in monotherapy and in combination with anti-PD1 and chemotherapy

MoA confirmed in multiple indications: Broad local and systemic immune activation associated with clinical outcome

Preparing a platform trial based on class-leading responses: 35% ORR in anti-PD1 refractory melanoma

Market Exclusivity: ONCOS-102 is protected by composition of matter and method of use patents until 2037, orphan drug designation in the US and EU and two FDA fast track designations

Pipeline assets: Expanding the pipeline of novel assets with collaboration partners, and a phase 2 ready mutRAS vaccine



FIRST HALF 2021 HIGHLIGHTS



FAST TRACK DESIGNATION

Fast track designation is given for new treatments that:

Requirements

- Are aimed at serious medical conditions
- Have demonstrated **potential to address the unmet medical need**

FDA commits to expedite development and review by:

Benefits

- Giving opportunities for **frequent interactions** with the review team
- Allowing for **rolling review** for a faster approval process
- Considering the option for **priority review**






Melanoma

- 3. Finance
- 4. Summary



ONCOS-102 HAS DEMONSTRATED CLASS-LEADING EFFICACY IN PD1-REFRACTORY MELANOMA



Targovax market analysis, March 2021.

8


1 Assuming 454 evaluable patients at 1:1 ratio per Company Presentation

WHAT CHARACTERIZES A GREAT IMMUNE ACTIVATOR?



Activate pro-inflammatory signalling pathways

- Trigger danger signalling, e.g. through TLR9 activation
- Stimulate release of cytokines and chemokines



Drive increased tumor immune cell infiltrate

- Break down tumor entry barriers
- Recruit T-cells, NK-cells, dendritic cells, macrophages



Facilitate priming of anti-tumor immune response

- Enhance processing of tumor antigens
- Stimulate maturation of antigen-presenting cells (APCs)




Counteract inhibitory molecular pathways and cell subsets


- Prevent T-cell exhaustion/anergy
- Diminish inhibitory cell subsets, e.g. T_{regs}, M2 macrophages



ONCOS-102 INCREASES TUMOR T-CELL INFILTRATION COMPLETE RESPONSE MELANOMA PATIENT CASE EXAMPLE




INCREASED T-CELL INFILTRATION FOLLOWING ONCOS-102 MONOTHERAPY IS CONSISTENT WITH MELANOMA PATIENT OUTCOMES



CD4+ helper T-cell infiltration


Average level by tumor response





HIGH RATIO OF ACTIVE CYTOTOXIC CD8+ T-CELLS INDICATE A "HOT" TUMOR MICROENVIRONMENT


GRB+ CD8+ T-cell infiltration; % of total CD8+ population





CONVERSELY, INHIBITORY T_{REGS} ARE DOWN-REGULATED IN RESPONDING MELANOMA PATIENTS

Regulatory T-cell infiltration; FOXP3+ % of total CD4+ population







GENE EXPRESSION DATA CONFIRMS IHC* OBSERVATIONS AND DETAILS BROAD PRO-INFLAMMATORY TUMOR RE-PROGRAMING

RNAseq gene expression provides further insights:

- **Pro-inflammatory "hot" tumor remodeling** through multiple pathways and molecular mechanisms
- Increased expression of chemokines and cytokines explain higher immune cell infiltrate
- Strong upregulation of cytotoxic machinery explains tumor shrinkage
- Upregulation of immunomodulatory molecules present targets for novel combinations beyond anti-PD1
- "Hot" tumor remodeling persists at least until week 9
- Potential genetic biomarker for patient selection identified through additional DNA sequencing




IMPORTANTLY, THESE OBSERVATIONS ARE CONSISTENT ACROSS TUMOR TYPES – MESOTHELIOMA EXAMPLE




IMMUNE MARKER DATA BUILD STRONG BIOLOGICAL RATIONALE FOR SEVERAL NEW COMBINATIONS WITH ONCOS-102

Immuno-modulation in tumor tissue; Mesothelioma, Day 36 vs. baseline




IMMUNE MARKER DATA BUILD STRONG BIOLOGICAL RATIONALE FOR SEVERAL NEW COMBINATIONS WITH ONCOS-102

Immuno-modulation in tumor tissue; Mesothelioma, Day 36 vs. baseline




STRENGTH AND BREADTH OF ONCOS-102 CLINICAL DATA PACKAGE OPENS BROAD OPPORTUNITIES





PLANNING A MELANOMA PHASE 2 PLATFORM TRIAL TO EXPLORE MULTIPLE ONCOS-102 COMBINATIONS

Part 1 – run-in



Part 2 – multi-cohort extension

- Additional cohorts to explore novel combinations
- Ability to add further cohorts along the way
- Aim to further boost response rates beyond 35% ORR
- Collaboration with partners dialogues ongoing

Cohorts 2 onward can independently form the basis for a subsequent registrational trial



CLINICAL AND PRECLINICAL PIPELINE

Product candidate	Preclinical	Phase 1	Phase 2	Phase 3	Next expected event	
	Refractory Melanoma Platform trial				1H 2022 First patient in	
ONCOS-102	Mesothelioma Combination w/pemetrexed	/cisplatin		2H 2021 Survival update		
	Metastatic Colorectal cance Combination w/anti PDL1	r			1H 2022 Clinical data	
Next Gen viruses					Preclinical data and selection of candidates	
Novel mutRAS concepts					Preclinical data and selection of candidates	





Finance

4. Summary



2Q FINANCIAL SNAPSHOT

Key figures



Shareholder base¹

Ownership by professional institutions, e.g.

• HealthCap, Nordea, Radforsk, AP4, Arctic Aurora, MP Pension **31%**

Largest shareholder

HealthCap

14%

Ownership by top 20 shareholders

48%

No of shareholders (approx.)


5600



SECOND QUARTER OPEX IN LINE WITH PREVIOUS QUARTERS


NOK m	2Q20	3Q20	4Q20	1Q21	2Q21
Total revenue	0	0	0	0	0
External R&D expenses ¹	-14	-9	-8	-9	-9
Payroll and related expenses	-11	-9	-12	-11	-13
Other operating expenses ²	-5	-4	-3	-2	-3
Total operating expenses	-30	-22	-23	-23	-25
Operating loss	-30	-22	-23	-23	-25
Net financial items	-4	-1	-3	1	-1
Loss before income tax	-33	-23	-26	-22	-26
Net change in cash	-34	-24	45	-27	-24
Net cash EOP	101	78	122	95	71







TARGOVAX AT A GLANCE



ONCOS-102: Novel immune activator with clinical efficacy in several solid tumors in monotherapy and in combination with anti-PD1 and chemotherapy

MoA confirmed in multiple indications: Broad local and systemic immune activation associated with clinical outcome

Preparing a platform trial based on class-leading responses: 35% ORR in PD-1 refractory melanoma

Market Exclusivity: ONCOS-102 is protected by composition of matter and method of use patents until 2037, orphan drug designation in the US and EU and two fast track designations

Pipeline assets: Expanding the pipeline of novel assets with collaboration partners, and a phase 2 ready mutRAS vaccine



Upcoming conferences / events

7 Sep 2021:	Next Gen Cancer Vaccine Development Summit
17-21 Sep 2021:	European Society for Medical Oncology (ESMO)
26 Oct 2021:	Oncolytic Virotherapy Summit
26-29 Oct 2021:	5th Annual Next Gen IO Conference EU edition

Upcoming data milestones

2H 2021:	ONCOS-102 in combination with chemotherapy in unresectable malignant pleural
	mesothelioma – Survival update

1H 2022:ONCOS-102 in combination with durvalumab in colorectal cancer with peritoneal
carcinomatosis – *Clinical and biomarker data*

Financial Calendar 2021

- 4 Nov 2021: Third Quarter presentation
- **17 Feb 2022:** Fourth Quarter presentation